Moses-Kolko, EL, Bogen, D, Perel, J, Bregar, A, Uhl, K, Levin, B, Wisner, KL. Neonatal signs after late in utero exposure to
serotonin reuptake inhibitors: literature review and implications for
clinical applications. JAMA
2005; 293: 2372–83.
Chambers, CD, Johnson, KA, Dick, LM, Felix, RJ, Jones, KL. Birth outcomes in pregnant women taking
fluoxetine. N Engl J Med
1996; 335: 1010–15.
Levinson-Castiel, R, Merlob, P, Linder, N, Sirota, L, Klinger, G. Neonatal abstinence syndrome after in utero exposure
to selective serotonin reuptake inhibitors in term
infants. Arch Pediatr Adolesc Med
2006; 160: 173–6.
Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, Werler, MM, Louik, C, Jones, KL, Mitchell, AA. Selective serotonin-reuptake inhibitors and risk of
persistent pulmonary hypertension of the newborn.
N Engl J Med
2006; 354: 579–87.
Oberlander, TF, Warburton, W, Misri, S, Aghajanian, J, Hertzman, C. Neonatal outcomes after prenatal exposure to
selective serotonin reuptake inhibitor antidepressants and maternal
depression using population-based linked health data.
Arch Gen Psychiatry
Chamberlayne, R, Green, B, Barer, ML, Hertzman, C, Lawrence, WJ, Sheps, SB. Creating a population-based linked health database:
a new resource for health services research. Can
J Public Health
1998; 89: 270–3.
Rosenbaum, PR, Rubin, DB. The central role of the propensity score in
observational studies for causal effects.
Foster, ME. Propensity score matching an illustrative analysis
of dose response. Med Care
2003; 41: 1183–92.
Heckman, JJ, Ichimura, H, Smith, J, Todd, P. Sources of selection bias in evaluating social
programs: an interpretation of conventional measures and evidence on the
effectiveness of matching as a program evaluation method.
Proc Natl Acad Sci USA
1996; 93: 13416–20.
Malm, H, Klaukka, T, Neuvonen, PJ. Risks associated with selective serotonin reuptake
inhibitors in pregnancy. Obstet Gynecol
2005; 106: 1289–96.
Simon, GE, Cunningham, ML, Davis, RL. Outcomes of prenatal antidepressant
exposure. Am J Psychiatry
2002; 159: 2055–61.
Kallen, B. Neonate characteristics after maternal use of
antidepressants in late pregnancy. Arch Pediatr
2004; 158: 312–6.
Evans, J, Heron, J, Francomb, H, Oke, S, Golding, J. Cohort study of depressed mood during pregnancy and
after childbirth. BMJ
2001; 323: 257–60.
Hill, JL, Reiter, J, Zanutto, EL. A comparison of experimental and observational data
analyses. In Applied Bayesian Modeling and Causal
Inference from an Incomplete-Data Perspective (eds Gelman, A, Meng, XL). Wiley,
Laine, K, Heikkinen, T, Ekblad, U, Kero, P. Effects of exposure to selective serotonin reuptake
inhibitors during pregnancy on serotonergic symptoms in newborns and cord
blood monoamine and prolactin concentrations.
Arch Gen Psychiatry
2003; 60: 720–6.
Oberlander, TF, Misri, S, Fitzgerald, CE, Kostaras, X, Rurak, D, Riggs, W. Pharmacologic factors associated with transient
neonatal symptoms following prenatal psychotropic medication
exposure. J Clin Psychiatry
2004; 65: 230–7.
Oberlander, TF, Eckstein, GR, Fitzgerald, C, Ellwood, AL, Misri, S, Rurak, D, Riggs, KW. Prolonged prenatal psychotropic medication exposure
alters neonatal acute pain response. Pediatr
2002; 51: 443–53.
Oberlander, TF, Grunau, RE, Fitzgerald, C, Papsdorf, M, Rurak, D, Riggs, W. Pain reactivity in 2-month-old infants after
prenatal and postnatal serotonin reuptake inhibitor medication
2005; 115: 411–25.
Lucki, I. The spectrum of behaviors influenced by
serotonin. Biol Psychiatry
1998; 44: 151–62.
Whitaker-Azmitia, PM, Druse, M, Walker, P, Lauder, JM. Serotonin as a developmental signal.
Behav Brain Res
Lauder, JM. Neurotransmitters as growth regulatory signals: role
of receptors and second messengers. Trends
1993; 16: 233–40.
Cabrera-Vera, TM, Battaglia, G. Prenatal exposure to fluoxetine (Prozac) produces
site-specific and age-dependent alterations in brain serotonin
transporters in rat progeny: evidence from autoradiographic
studies. J Pharmacol Exp Ther
1998; 286: 1474–81.
Wisner, KL, Zarin, DA, Holmboe, ES, Appelbaum, PS, Gelenberg, AJ, Leonard, HL, Frank, E. Risk-benefit decision making for treatment of
depression during pregnancy. Am J
2000; 157: 1933–40.